 |
PDBsum entry 1qub
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Membrane adhesion
|
PDB id
|
|
|
|
1qub
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Membrane adhesion
|
 |
|
Title:
|
 |
Crystal structure of the glycosylated five-domain human beta2- glycoprotein i purified from blood plasma
|
|
Structure:
|
 |
Protein (human beta2-glycoprotein i). Chain: a. Fragment: beta2-glycoprotein i
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Organelle: blood plasma
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.70Å
|
R-factor:
|
0.249
|
R-free:
|
0.269
|
|
|
Authors:
|
 |
B.Bouma,P.G.De Groot,J.M.H.Van Den Elsen,R.B.G.Ravelli,A.Schouten, M.J.A.Simmelink,R.H.W.M.Derksen,J.Kroon,P.Gros
|
Key ref:
|
 |
B.Bouma
et al.
(1999).
Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure.
EMBO J,
18,
5166-5174.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
01-Jul-99
|
Release date:
|
08-Oct-99
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P02749
(APOH_HUMAN) -
Beta-2-glycoprotein 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
345 a.a.
319 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
EMBO J
18:5166-5174
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure.
|
|
B.Bouma,
P.G.de Groot,
J.M.van den Elsen,
R.B.Ravelli,
A.Schouten,
M.J.Simmelink,
R.H.Derksen,
J.Kroon,
P.Gros.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Human beta(2)-glycoprotein I is a heavily glycosylated five-domain plasma
membrane-adhesion protein, which has been implicated in blood coagulation and
clearance of apoptotic bodies from the circulation. It is also the key antigen
in the autoimmune disease anti-phospholipid syndrome. The crystal structure of
beta(2)-glycoprotein I isolated from human plasma reveals an elongated
fish-hook-like arrangement of the globular short consensus repeat domains. Half
of the C-terminal fifth domain deviates strongly from the standard fold, as
observed in domains one to four. This aberrant half forms a specific
phospholipid-binding site. A large patch of 14 positively charged residues
provides electrostatic interactions with anionic phospholipid headgroups and an
exposed membrane-insertion loop yields specificity for lipid layers. The
observed spatial arrangement of the five domains suggests a functional
partitioning of protein adhesion and membrane adhesion over the N- and
C-terminal domains, respectively, separated by glycosylated bridging domains.
Coordinates are in the Protein Data Bank (accession No. 1QUB).
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1 Structural representations of human blood plasma 2GPI
revealing the extended chain of the five SCR domains. (A) Ribbon
drawing of 2GPI
with consecutive domains labelled I -V. N-linked glycans, as
well as the position of the putative O-linked glycan, Thr130,
are indicated by a ball-and-stick model. -strands
are shown in red and helices in green. (B) Topology diagram of
2GPI.
The central -sheets
of all five domains are labelled B2(-B2")-B3-B4(-B5), the N- and
C-terminal -sheets
are labelled B1'-B2' and B4'-B5', the -helix
and the 3/10 helix are denoted A1 and A2 and numbers of residues
delimiting secondary structure elements are given. Disulfide
bonds are indicated with dashed lines. The positions of
N-glycosylation are given by hexagons; a diamond indicates the
putative O-glycan. Horizontal dashed lines mark domain
boundaries. (C) Ribbon representation of domain III of 2GPI
with labelled secondary structure elements. The two fully
conserved disulfide bonds are shown in yellow. (D) Ribbon
representation of domain V of 2GPI
with labelled secondary structure elements. The three disulfide
bonds are indicated with yellow lines. The aberrant face, which
contains the membrane-binding site, is located on the right-hand
side.
|
 |
Figure 5.
Figure 5 Binding of 2GPI
to an anionic phospholipid surface. (A) Two views, related by
180° rotation, of the electrostatic potential surface of 2GPI.
Domains are labelled I -V. The electrostatic potential is scaled
from red for negative to blue for positive. (B) Positively
charged patch on the aberrant half of domain V. The 14 residues
contributing to this patch and the position of the disordered
loop Ser311 -Lys317 are indicated. (C) Diagram of the proposed
model for binding of 2GPI
to acidic phospholipids. The positively charged patch on the
surface of domain V is indicated by '+', acidic phospholipids
are depicted by '-' and the putative membrane-insertion loop
Ser311 -Ser -Leu -Ala -Phe -Trp -Lys317 is shown to insert into
the phospholipid layer. The positions of N-glycans are indicated
by hexagons and the putative site for O-linked glycosylation is
indicated by a diamond.
|
 |
|
|
|
| |
The above figures are
reprinted
from an Open Access publication published by Macmillan Publishers Ltd:
EMBO J
(1999,
18,
5166-5174)
copyright 1999.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
B.Giannakopoulos,
P.Mirarabshahi,
and
S.A.Krilis
(2011).
New insights into the biology and pathobiology of beta2-glycoprotein I.
|
| |
Curr Rheumatol Rep,
13,
90-95.
|
 |
|
|
|
|
 |
B.de Laat,
and
P.G.de Groot
(2011).
Autoantibodies directed against domain I of beta2-glycoprotein I.
|
| |
Curr Rheumatol Rep,
13,
70-76.
|
 |
|
|
|
|
 |
I.Azimi,
J.W.Wong,
and
P.J.Hogg
(2011).
Control of mature protein function by allosteric disulfide bonds.
|
| |
Antioxid Redox Signal,
14,
113-126.
|
 |
|
|
|
|
 |
I.Dienava-Verdoold,
M.G.Boon-Spijker,
P.G.de Groot,
H.J.Brinkman,
J.Voorberg,
K.Mertens,
R.H.Derksen,
and
B.de Laat
(2011).
Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity.
|
| |
J Thromb Haemost,
9,
738-747.
|
 |
|
|
|
|
 |
M.Bohgaki,
M.Matsumoto,
T.Atsumi,
T.Kondo,
S.Yasuda,
T.Horita,
K.I.Nakayama,
F.Okumura,
S.Hatakeyama,
and
T.Koike
(2011).
Plasma gelsolin facilitates interaction between β2 glycoprotein I and α5β1 integrin.
|
| |
J Cell Mol Med,
15,
141-151.
|
 |
|
|
|
|
 |
M.E.Bohlin,
L.G.Blomberg,
and
N.H.Heegaard
(2011).
Effects of ionic strength, temperature and conformation on affinity interactions of β₂-glycoprotein I monitored by capillary electrophoresis.
|
| |
Electrophoresis,
32,
728-737.
|
 |
|
|
|
|
 |
R.T.Urbanus,
and
P.G.de Groot
(2011).
Antiphospholipid antibodies--we are not quite there yet.
|
| |
Blood Rev,
25,
97.
|
 |
|
|
|
|
 |
C.Agar,
G.M.van Os,
M.Mörgelin,
R.R.Sprenger,
J.A.Marquart,
R.T.Urbanus,
R.H.Derksen,
J.C.Meijers,
and
P.G.de Groot
(2010).
Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome.
|
| |
Blood,
116,
1336-1343.
|
 |
|
|
|
|
 |
C.J.Lee,
A.De Biasio,
and
N.Beglova
(2010).
Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids.
|
| |
Structure,
18,
366-376.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.H.Passam,
S.Rahgozar,
M.Qi,
M.J.Raftery,
J.W.Wong,
K.Tanaka,
Y.Ioannou,
J.Y.Zhang,
R.Gemmell,
J.C.Qi,
B.Giannakopoulos,
W.E.Hughes,
P.J.Hogg,
and
S.A.Krilis
(2010).
Beta 2 glycoprotein I is a substrate of thiol oxidoreductases.
|
| |
Blood,
116,
1995-1997.
|
 |
|
|
|
|
 |
F.H.Passam,
S.Rahgozar,
M.Qi,
M.J.Raftery,
J.W.Wong,
K.Tanaka,
Y.Ioannou,
J.Y.Zhang,
R.Gemmell,
J.C.Qi,
B.Giannakopoulos,
W.E.Hughes,
P.J.Hogg,
and
S.A.Krilis
(2010).
Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1.
|
| |
J Thromb Haemost,
8,
1754-1762.
|
 |
|
|
|
|
 |
J.H.Rand
(2010).
A snappy new concept for APS.
|
| |
Blood,
116,
1193-1194.
|
 |
|
|
|
|
 |
K.Cupelli,
S.Müller,
B.D.Persson,
M.Jost,
N.Arnberg,
and
T.Stehle
(2010).
Structure of adenovirus type 21 knob in complex with CD46 reveals key differences in receptor contacts among species B adenoviruses.
|
| |
J Virol,
84,
3189-3200.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Blank,
and
Y.Shoenfeld
(2010).
Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome.
|
| |
Clin Rev Allergy Immunol,
38,
141-147.
|
 |
|
|
|
|
 |
M.P.Sikara,
J.G.Routsias,
M.Samiotaki,
G.Panayotou,
H.M.Moutsopoulos,
and
P.G.Vlachoyiannopoulos
(2010).
{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome.
|
| |
Blood,
115,
713-723.
|
 |
|
|
|
|
 |
N.Pozzi,
A.Banzato,
S.Bettin,
E.Bison,
V.Pengo,
and
V.De Filippis
(2010).
Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I.
|
| |
Protein Sci,
19,
1065-1078.
|
 |
|
|
|
|
 |
P.G.Vlachoyiannopoulos,
and
J.G.Routsias
(2010).
A novel mechanism of thrombosis in antiphospholipid antibody syndrome.
|
| |
J Autoimmun,
35,
248-255.
|
 |
|
|
|
|
 |
Y.Ioannou,
J.Y.Zhang,
F.H.Passam,
S.Rahgozar,
J.C.Qi,
B.Giannakopoulos,
M.Qi,
P.Yu,
D.M.Yu,
P.J.Hogg,
and
S.A.Krilis
(2010).
Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury.
|
| |
Blood,
116,
1961-1970.
|
 |
|
|
|
|
 |
D.Beglov,
C.J.Lee,
A.De Biasio,
D.Kozakov,
R.Brenke,
S.Vajda,
and
N.Beglova
(2009).
Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors.
|
| |
Proteins,
77,
940-949.
|
 |
|
|
|
|
 |
J.Wu,
Y.Q.Wu,
D.Ricklin,
B.J.Janssen,
J.D.Lambris,
and
P.Gros
(2009).
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.
|
| |
Nat Immunol,
10,
728-733.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.Matsuura,
G.R.Hughes,
and
M.A.Khamashta
(2008).
Oxidation of LDL and its clinical implication.
|
| |
Autoimmun Rev,
7,
558-566.
|
 |
|
|
|
|
 |
H.Mehdi,
A.Naqvi,
and
M.I.Kamboh
(2008).
Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H).
|
| |
Biochim Biophys Acta,
1782,
163-168.
|
 |
|
|
|
|
 |
J.D.Burman,
E.Leung,
K.L.Atkins,
M.N.O'Seaghdha,
L.Lango,
P.Bernadó,
S.Bagby,
D.I.Svergun,
T.J.Foster,
D.E.Isenman,
and
J.M.van den Elsen
(2008).
Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus.
|
| |
J Biol Chem,
283,
17579-17593.
|
 |
|
|
|
|
 |
J.H.Rand,
X.X.Wu,
A.S.Quinn,
P.P.Chen,
J.J.Hathcock,
and
D.J.Taatjes
(2008).
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.
|
| |
Blood,
112,
1687-1695.
|
 |
|
|
|
|
 |
J.Urbanija,
B.Babnik,
M.Frank,
N.Tomsic,
B.Rozman,
V.Kralj-Iglic,
and
A.Iglic
(2008).
Attachment of beta 2-glycoprotein I to negatively charged liposomes may prevent the release of daughter vesicles from the parent membrane.
|
| |
Eur Biophys J,
37,
1085-1095.
|
 |
|
|
|
|
 |
R.T.Urbanus,
R.H.Derksen,
and
P.G.de Groot
(2008).
Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome.
|
| |
Blood Rev,
22,
93.
|
 |
|
|
|
|
 |
S.N.Maiti,
K.Balasubramanian,
J.A.Ramoth,
and
A.J.Schroit
(2008).
Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members.
|
| |
J Biol Chem,
283,
3761-3766.
|
 |
|
|
|
|
 |
I.Krause,
M.Blank,
R.Cervera,
J.Font,
T.Matthias,
S.Pfeiffer,
I.Wies,
A.Fraser,
and
Y.Shoenfeld
(2007).
Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome.
|
| |
Ann N Y Acad Sci,
1108,
481-488.
|
 |
|
|
|
|
 |
J.H.Rand
(2007).
The antiphospholipid syndrome.
|
| |
Hematology Am Soc Hematol Educ Program,
2007,
136-142.
|
 |
|
|
|
|
 |
K.Kobayashi,
L.R.Lopez,
and
E.Matsuura
(2007).
Atherogenic antiphospholipid antibodies in antiphospholipid syndrome.
|
| |
Ann N Y Acad Sci,
1108,
489-496.
|
 |
|
|
|
|
 |
M.T.Pennings,
R.H.Derksen,
M.van Lummel,
J.Adelmeijer,
K.VanHoorelbeke,
R.T.Urbanus,
T.Lisman,
and
P.G.de Groot
(2007).
Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'.
|
| |
J Thromb Haemost,
5,
369-377.
|
 |
|
|
|
|
 |
N.Di Simone,
M.P.Luigi,
D.Marco,
D.N.Fiorella,
D.Silvia,
D.M.Clara,
and
C.Alessandro
(2007).
Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature.
|
| |
Ann N Y Acad Sci,
1108,
505-514.
|
 |
|
|
|
|
 |
S.Sodin-Semrl,
and
B.Rozman
(2007).
Beta2-glycoprotein I and its clinical significance: from gene sequence to protein levels.
|
| |
Autoimmun Rev,
6,
547-552.
|
 |
|
|
|
|
 |
T.Kajiwara,
T.Yasuda,
and
E.Matsuura
(2007).
Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome.
|
| |
J Autoimmun,
29,
164-173.
|
 |
|
|
|
|
 |
T.Koike,
and
T.Atsumi
(2007).
"Resurrection of thrombin" in the pathophysiology of the antiphospholipid syndrome.
|
| |
Arthritis Rheum,
56,
393-394.
|
 |
|
|
|
|
 |
T.Sakai,
K.Balasubramanian,
S.Maiti,
J.B.Halder,
and
A.J.Schroit
(2007).
Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.
|
| |
Am J Pathol,
171,
1659-1669.
|
 |
|
|
|
|
 |
Y.Ioannou,
C.Pericleous,
I.Giles,
D.S.Latchman,
D.A.Isenberg,
and
A.Rahman
(2007).
Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43.
|
| |
Arthritis Rheum,
56,
280-290.
|
 |
|
|
|
|
 |
A.Ambrozic,
S.Cucnik,
N.Tomsic,
J.Urbanija,
M.Lokar,
B.Babnik,
B.Rozman,
A.Iglic,
and
V.Kralj-Iglic
(2006).
Interaction of giant phospholipid vesicles containing cardiolipin and cholesterol with beta2-glycoprotein-I and anti-beta2-glycoprotein-I antibodies.
|
| |
Autoimmun Rev,
6,
10-15.
|
 |
|
|
|
|
 |
C.Licht,
S.Heinen,
M.Józsi,
I.Löschmann,
R.E.Saunders,
S.J.Perkins,
R.Waldherr,
C.Skerka,
M.Kirschfink,
B.Hoppe,
and
P.F.Zipfel
(2006).
Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).
|
| |
Kidney Int,
70,
42-50.
|
 |
|
|
|
|
 |
P.G.Vlachoyiannopoulos,
and
M.Samarkos
(2006).
Pathogenetic potential of antiphospholipid antibodies.
|
| |
Future Cardiol,
2,
303-314.
|
 |
|
|
|
|
 |
R.E.Saunders,
T.H.Goodship,
P.F.Zipfel,
and
S.J.Perkins
(2006).
An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations.
|
| |
Hum Mutat,
27,
21-30.
|
 |
|
|
|
|
 |
A.Ambrozic,
B.Bozic,
T.Kveder,
J.Majhenc,
V.Arrigler,
S.Svetina,
and
B.Rozman
(2005).
Budding, vesiculation and permeabilization of phospholipid membranes-evidence for a feasible physiologic role of beta2-glycoprotein I and pathogenic actions of anti-beta2-glycoprotein I antibodies.
|
| |
Biochim Biophys Acta,
1740,
38-44.
|
 |
|
|
|
|
 |
K.Balasubramanian,
S.N.Maiti,
and
A.J.Schroit
(2005).
Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis.
|
| |
Apoptosis,
10,
439-446.
|
 |
|
|
|
|
 |
K.Kobayashi,
L.R.Lopez,
Y.Shoenfeld,
and
E.Matsuura
(2005).
The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis.
|
| |
Ann N Y Acad Sci,
1051,
442-454.
|
 |
|
|
|
|
 |
L.Aldaz-Carroll,
J.C.Whitbeck,
M.Ponce de Leon,
H.Lou,
L.Hirao,
S.N.Isaacs,
B.Moss,
R.J.Eisenberg,
and
G.H.Cohen
(2005).
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.
|
| |
J Virol,
79,
6260-6271.
|
 |
|
|
|
|
 |
M.van Lummel,
M.T.Pennings,
R.H.Derksen,
R.T.Urbanus,
B.C.Lutters,
N.Kaldenhoven,
and
P.G.de Groot
(2005).
The binding site in {beta}2-glycoprotein I for ApoER2' on platelets is located in domain V.
|
| |
J Biol Chem,
280,
36729-36736.
|
 |
|
|
|
|
 |
O.Safa,
C.T.Esmon,
and
N.L.Esmon
(2005).
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.
|
| |
Blood,
106,
1629-1635.
|
 |
|
|
|
|
 |
P.G.de Groot,
and
R.H.Derksen
(2005).
Pathophysiology of the antiphospholipid syndrome.
|
| |
J Thromb Haemost,
3,
1854-1860.
|
 |
|
|
|
|
 |
S.Yasuda,
T.Atsumi,
E.Matsuura,
K.Kaihara,
D.Yamamoto,
K.Ichikawa,
and
T.Koike
(2005).
Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant.
|
| |
Arthritis Rheum,
52,
212-218.
|
 |
|
|
|
|
 |
T.Atsumi,
O.Amengual,
S.Yasuda,
E.Matsuura,
and
T.Koike
(2005).
Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies.
|
| |
Autoimmunity,
38,
377-381.
|
 |
|
|
|
|
 |
T.Shi,
B.Giannakopoulos,
G.M.Iverson,
K.A.Cockerill,
M.D.Linnik,
and
S.A.Krilis
(2005).
Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318.
|
| |
J Biol Chem,
280,
907-912.
|
 |
|
|
|
|
 |
S.Yasuda
(2004).
[Pathogenic roles of anti-beta2-GPI antibody in patients with antiphospholipid syndrome]
|
| |
Nihon Rinsho Meneki Gakkai Kaishi,
27,
373-378.
|
 |
|
|
|
|
 |
I.P.Giles,
D.A.Isenberg,
D.S.Latchman,
and
A.Rahman
(2003).
How do antiphospholipid antibodies bind beta2-glycoprotein I?
|
| |
Arthritis Rheum,
48,
2111-2121.
|
 |
|
|
|
|
 |
J.Arnout,
and
J.Vermylen
(2003).
Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease.
|
| |
J Thromb Haemost,
1,
931-942.
|
 |
|
|
|
|
 |
J.H.Rand
(2003).
The antiphospholipid syndrome.
|
| |
Annu Rev Med,
54,
409-424.
|
 |
|
|
|
|
 |
J.H.Rand,
X.X.Wu,
A.S.Quinn,
P.P.Chen,
K.R.McCrae,
E.G.Bovill,
and
D.J.Taatjes
(2003).
Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.
|
| |
Am J Pathol,
163,
1193-1200.
|
 |
|
|
|
|
 |
M.Kuwana
(2003).
Autoreactive CD4(+) T cells to beta(2)-glycoprotein I in patients with antiphospholipid syndrome.
|
| |
Autoimmun Rev,
2,
192-198.
|
 |
|
|
|
|
 |
B.O.Smith,
R.L.Mallin,
M.Krych-Goldberg,
X.Wang,
R.E.Hauhart,
K.Bromek,
D.Uhrin,
J.P.Atkinson,
and
P.N.Barlow
(2002).
Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor.
|
| |
Cell,
108,
769-780.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Matsuura,
K.Kobayashi,
J.Kasahara,
T.Yasuda,
H.Makino,
T.Koike,
and
Y.Shoenfeld
(2002).
Anti-beta 2-glycoprotein I autoantibodies and atherosclerosis.
|
| |
Int Rev Immunol,
21,
51-66.
|
 |
|
|
|
|
 |
F.Wang,
X.F.Xia,
and
S.F.Sui
(2002).
Human apolipoprotein H may have various orientations when attached to lipid layer.
|
| |
Biophys J,
83,
985-993.
|
 |
|
|
|
|
 |
G.M.Iverson,
E.Matsuura,
E.J.Victoria,
K.A.Cockerill,
and
M.D.Linnik
(2002).
The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA.
|
| |
J Autoimmun,
18,
289-297.
|
 |
|
|
|
|
 |
M.Budayova-Spano,
M.Lacroix,
N.M.Thielens,
G.J.Arlaud,
J.C.Fontecilla-Camps,
and
C.Gaboriaud
(2002).
The crystal structure of the zymogen catalytic domain of complement protease C1r reveals that a disruptive mechanical stress is required to trigger activation of the C1 complex.
|
| |
EMBO J,
21,
231-239.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Gaudier,
Y.Gaudin,
and
M.Knossow
(2002).
Crystal structure of vesicular stomatitis virus matrix protein.
|
| |
EMBO J,
21,
2886-2892.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.A.Cocca,
S.N.Seal,
P.D'Agnillo,
Y.M.Mueller,
P.D.Katsikis,
J.Rauch,
M.Weigert,
and
M.Z.Radic
(2001).
Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein I and apoptotic cells.
|
| |
Proc Natl Acad Sci U S A,
98,
13826-13831.
|
 |
|
|
|
|
 |
K.H.Murthy,
S.A.Smith,
V.K.Ganesh,
K.W.Judge,
N.Mullin,
P.N.Barlow,
C.M.Ogata,
and
G.J.Kotwal
(2001).
Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans.
|
| |
Cell,
104,
301-311.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Weik,
G.Kryger,
A.M.Schreurs,
B.Bouma,
I.Silman,
J.L.Sussman,
P.Gros,
and
J.Kroon
(2001).
Solvent behaviour in flash-cooled protein crystals at cryogenic temperatures.
|
| |
Acta Crystallogr D Biol Crystallogr,
57,
566-573.
|
 |
|
|
|
|
 |
A.T.Lee,
K.Balasubramanian,
and
A.J.Schroit
(2000).
beta(2)-glycoprotein I-dependent alterations in membrane properties.
|
| |
Biochim Biophys Acta,
1509,
475-484.
|
 |
|
|
|
|
 |
K.Ma,
R.Simantov,
J.C.Zhang,
R.Silverstein,
K.A.Hajjar,
and
K.R.McCrae
(2000).
High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II.
|
| |
J Biol Chem,
275,
15541-15548.
|
 |
|
|
|
|
 |
M.D.Lockshin
(2000).
Future trends for treatment of APS.
|
| |
J Autoimmun,
15,
261-264.
|
 |
|
|
|
|
 |
P.G.de Groot G,
B.Bouma,
B.C.Lutters,
M.J.Simmelink,
R.H.Derksen,
and
P.Gros
(2000).
Structure-function studies on beta 2-glycoprotein I.
|
| |
J Autoimmun,
15,
87-89.
|
 |
|
|
|
|
 |
R.A.Roubey
(2000).
Update on antiphospholipid antibodies.
|
| |
Curr Opin Rheumatol,
12,
374-378.
|
 |
|
|
|
|
 |
R.A.Roubey
(2000).
Antiphospholipid syndrome: antibodies and antigens.
|
| |
Curr Opin Hematol,
7,
316-320.
|
 |
|
|
|
|
 |
T.Koike,
K.Ichikawa,
T.Atsumi,
H.Kasahara,
and
E.Matsuura
(2000).
Beta 2-glycoprotein I-anti-beta 2-glycoprotein I interaction.
|
| |
J Autoimmun,
15,
97.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |